On March 30, 2020 BerGenBio, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, reported that Richard Godfrey, Chief Executive Officer, will present at the upcoming Solebury Trout Virtual Investor Conference (Press release, BerGenBio, MAR 30, 2020, View Source [SID1234555978]). The 25 minute presentation includes an interactive Q&A with participants prompted to submit questions electronically. Details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date/Time: Tuesday March 31, at 11am EDT

Access: https://78449.themediaframe.com/dataconf/productusers/solebury/mediaframe/36522/indexl.html

Webcast archive: 24 hours following the presentation an archive copy of the presentation will be available on the Company’s website at View Source